Expanded portfolio offerings include first-to-market product launches to support global health challenges New infectious disease research solutions to be spotlighted at ASM Microbe 2025

The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and speedy speech.

A solar-powered nitrate treatment unit is installed to demonstrate circular resource recovery

White glove manufacturing service aims to enhance design-build-test cycle and drive rapid innovation

Aldevron and Integrated DNA Technologies – both part of the Danaher Corporation – have achieved a medical milestone with the successful manufacture of the world’s first personalized CRISPR gene-editing drug product to treat an infant suffering from a rare and life-threatening genetic condition known as urea cycle disorder (UCD).

Steven Davis, Co-Founder and CEO of Bio::Neos, Inc. —a BioVentures Center tenant—received the Youth Engagement Award.

SunHydrogen has contracted The Process Group, LLC (TPG Engineers) for front-end engineering design of a >25-square-meter proof-of-concept hydrogen production pilot plant.

S5G Therapeutics, a startup comprised of experts in clinical and translational medicine, biomedical research, pharmaceutical sciences, and business development in the ocular therapeutics space, was awarded first place and $50,000 in the Graduate/Faculty/Staff/Incubator Startup division of Innovation Challenge.

Perspective Therapeutics has announced the first patient was treated with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α).